Table 6.
Univariate analysis of the impact of expression of serine/glycine metabolism-related proteins in breast cancers on disease-free survival and overall survival by the log-rank test
|
Parameter |
Number of patients/recurrence/death |
Disease-free survival |
Overall survival |
||
|---|---|---|---|---|---|
| Mean survival (95% CI) months | P -value | Mean survival (95% CI) months | P -value | ||
| GNMT |
|
|
0.042 |
|
0.498 |
| Negative |
664/54/55 |
127 (123–130) |
|
129 (127–132) |
|
| Positive |
57/9/6 |
98 (91–106) |
|
126 (116–135) |
|
| SARDH |
|
|
0.767 |
|
0.264 |
| Negative |
597/53/47 |
126 (122–130) |
|
130 (127–133) |
|
| Positive |
124/10/14 |
121 (115–127) |
|
124 (117–132) |
|
| PIPOX (T) |
|
|
0.039 |
|
0.361 |
| Negative |
570/57/52 |
126 (123–129) |
|
129 (126–131) |
|
| Positive |
151/6/9 |
123 (117–129) |
|
131 (126–135) |
|
| PIPOX (S) |
|
|
0.927 |
|
0.636 |
| Negative |
671/59/58 |
126 (122–130) |
|
129 (126–132) |
|
| Positive |
50/4/3 |
122 (114–130) |
|
126 (119–132) |
|
|
Sarcosine metabolic type |
|
|
0.021 |
|
0.503 |
| High sarcosine type |
36/8/5 |
90 (79–101) |
|
118 (106–130) |
|
| Intermediate sarcosine type |
21/1/1 |
108 (102–114) |
|
132 (122–143) |
|
| Low sarcosine type |
219/15/20 |
120 (115–125) |
|
126 (121–132) |
|
| Null type | 445/39/35 | 127 (124–131) | 130 (127–133) | ||
Bold number represents p<0.05.